Illustration of tumour progression and treatment response.

<p>T2w-MRI and fused ¹⁸F-FET MicroPET/CT images showing tumour progression 3–5 weeks after tumour cell injection. Transverse views through the brain of a mouse from the B20–4.1 group and a mouse from the control group. Scale bar: 0–1.4 SUV_max</p

Gene expression analysis of xenograft tumours.

<p>Gene expression of A) PlGF and B) VEGFR-1 in xenografts and a panel of GBM patients including patient GBM017. Values in xenografts are expressed as mean ± SEM (n = 12). C) Xenograft gene expression of PlGF in the control group (n = 4), the B20 group (n = 4). All genes are normalized to reference genes and are relative to human HMVEC</p

Immunohistochemistry of xenograft tumours.

<p>A) Representative IHC images of HE and high magnification of Ki67 (40x) and CD31 (20x). B) Ki67 proliferation index and C) MVD in the control group (n = 11), the B20 group (n = 10) and the B20+TB403 group (n = 7). Mean ± SEM, **p<0.01</p

Bioluminescence imaging to monitor treatment response.

<p>A) Representative images of bioluminescence 3–5 weeks after tumour cell injection showing tumour progression in a B20–4.1 mouse and a control mouse. B) Quantification of total flux relative to baseline (week 0). Values are expressed as mean ± SEM after one week of treatment in the control (n = 13), the B20 group (n = 11) and the B20+TB403 group (n = 8); and after two weeks of treatment in the control (n = 9), the B20 (n = 9) and the B20+TB403 group (n = 6). *<i>p</i><0.05</p

Survival analysis.

<p>Kaplan Meier survival curves from tumour take. Control group vs. B20 group, 13 vs. 21 days; p = 0.04; HR = 0.5; 95% CI: 0.13–0.82 (determined by log-rank test). E: events, N: number of animals</p

¹⁸F-FET MicroPET/CT to monitor treatment response.

<p>¹⁸F-FET uptake in the treatment groups expressed as A) SUV_max T/B ratio, B) SUV_mean T/B ratio and C) SUV_max. D) MRI volume in the treatment groups. All values are expressed as mean ± SEM relative to baseline (week 0) after 1 week of treatment in the control (n = 13), the B20 group (n = 11) and in the B20+TB403 (n = 9); and after 2 weeks of treatment in the control (n = 5), the B20 group (n = 8) and in the B20+TB403 group (n = 6). *<i>p</i><0.05, **p<0.01</p